来那度胺
医学
内科学
多发性骨髓瘤
不利影响
维持疗法
肿瘤科
造血干细胞移植
置信区间
临床研究阶段
沙利度胺
干细胞
移植
造血
临床试验
总体生存率
外科
血液学
无进展生存期
自体干细胞移植
胃肠病学
随机对照试验
作者
Matthew J. Rees,Masa Lasica,Anna Kalff,Michael Sze Yuan Low,Rosemary Anne Harrup,Hock Choong Lai,M Hasib Sidiqi,Nicole Wong Doo,David J. M. Routledge,Jay Hocking,Philip J. Campbell,Jessica Heenan,Noemi Horvath,Nicole Chien,William E. P. Renwick,Georgia J. B. McCaughan,Richard Wilhelm Eek,Douglas Stuart Lenton,Tricia Wright,Sher Gul Gazdar
摘要
SeaLAND (ALLG MM23, ACTRN12620000291987) was a randomized, open-label phase III study evaluating low-dose weekly selinexor (40 mg) plus lenalidomide (selinexor-R) versus lenalidomide alone (R) as post-transplant maintenance therapy for newly diagnosed, transplant-eligible multiple myeloma. A total of 142 patients were enrolled (R = 64; selinexor-R = 78); the trial closed early for futility. At best response, the complete response (≥CR) rate was numerically, but not significantly, higher with selinexor-R than R (67% vs. 53%, p = 0.09). At 24 months median follow-up, progression-free survival (PFS) was not significantly different between selinexor-R compared to R (hazard ratio [HR] = 1.22; 95% confidence interval [CI] 0.62-2.41; p = 0.56); 24-month PFS rates were 73% (95% CI 57%-84%) for R and 70% (95% CI: 56%-81%) for selinexor-R. The mean relative dose intensity (RDI) of R was lower in the selinexor-R arm compared to R alone (68% vs. 81%, p = 0.002); the mean RDI of S was 55%. Grade ≥3 adverse events were more frequent with selinexor-R (85% vs. 45%, p < 0.001). Common severe non-haematological adverse events included infections (R: 6%, selinexor-R: 19%, p < 0.01) and gastrointestinal disorders (R: 3%, selinexor-R: 14%, p < 0.05). Selinexor-R maintenance did not improve PFS and substantially increased toxicity. Selinexor-R maintenance cannot be recommended for the general myeloma population; we did not observe a benefit among high-risk disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI